New Medicines and Gene Therapy for Sickle Cell Disease: How to Check Research, Treatment Access, and Care Abroad
After seeing news about a new medicine or gene editing for sickle cell disease, first note the medicine’s full name, study registration number, and country where you plan to seek care. Then ask your hematologist whether it is relevant to your genotype, history of crises, and treatment goals. Regulatory approval, study registration, and a hospital’s actual acceptance of patients are separate matters. Get confirmation from the receiving center before booking tickets or paying.
Key points
- A fever of 38.5°C or higher, difficulty breathing, chest pain, sudden limb weakness, or speech changes require immediate care at a local emergency department. Do not delay emergency treatment to apply for a study. Severe pain or symptoms clearly different from your usual symptoms also need prompt medical attention.[1]
- The approved indications for Casgevy differ in the United States, United Kingdom, and European Union. Meeting the age requirement does not mean the treatment is suitable for you. Cell therapy involves cell collection, myeloablation, hospitalization, and long-term follow-up.[2–5]
- A study registration number helps you find the protocol; it does not prove that a particular hospital has places available today. First ask the study center to confirm recruitment, acceptance of international patients, screening arrangements, costs, and care after withdrawal.[10–12]
- For this guide, no available places in China were confirmed for the studies discussed, and approval or supply of Casgevy or Lyfgenia in China was not confirmed. Check with the hospital where you plan to receive care and the relevant regulators. Do not infer from this that access is necessarily impossible.
Distinguish approved treatment from research
As of November 6, 2026, the table below provides only a summary of the indications in the regulatory jurisdictions listed. Approval does not mean that every local hospital has the medicine, that costs are reimbursable, or that international patients can necessarily receive treatment.
| Treatment or study | Current evidence and status | What to check next |
|---|---|---|
| Casgevy (exagamglogene autotemcel) | The US FDA product page lists two records: STN 125787 for patients aged 2 years and older, and STN 125785 for patients aged 12 years and older, with sickle cell disease and recurrent vaso-occlusive crises. Ask the treatment center to check the product’s current prescribing information to determine which applies. In October 2026, the UK extended authorization for severe sickle cell disease to patients aged 5 years and older. The current EU EMA page still specifies patients aged 12 years and older with severe disease and recurrent crises, who are suitable for hematopoietic stem cell transplantation and do not have a suitable HLA-matched related donor.[2–4] | Ask the destination center for the latest approved indications, individual assessment criteria, actual availability, and payment conditions. The US evidence for younger children includes some extrapolation; ask about direct observations relevant to your child’s age and the remaining uncertainties.[2] |
| Lyfgenia (lovotibeglogene autotemcel) | Approved in the United States for patients aged 12 years and older with a history of vaso-occlusive events. Its label carries a boxed warning for blood cancers and requires lifelong monitoring.[5] | Discuss myeloablation, fertility, and long-term blood monitoring with the team. Do not assume that the two products have the same risks. |
| Etavopivat, mitapivat, risto-cel | Their clinical studies are described below. Study results do not mean a product is approved in China or available at a particular center.[6–9] | Use the medicine’s full name and study registration number to check the latest status, then confirm with the specific center. |
These conclusions cannot be applied directly outside the countries where approval has been granted. Whether a product can legally be provided in China, whether a hospital accepts patients, whether access is part of research, and what costs and eligibility requirements apply must all be checked for the specific product and institution.
What cell and gene therapy involve
Casgevy uses the patient’s own gene-edited blood-forming stem cells; Lyfgenia uses the patient’s own cells modified by gene addition. The usual process involves assessment, cell collection, product manufacturing and release, followed by myeloablative conditioning, cell infusion, and a wait for blood counts to recover.[2,5] Collection or manufacturing may fail, or treatment may need to be rescheduled. Ask the center to explain the backup plan and costs in these situations.
Myeloablation lowers blood cell counts, increasing the risk of serious infection, bleeding, and other complications. It may also affect fertility. Before treatment, ask the team to explain fertility preservation options and timing, hospital and isolation arrangements, organ function assessments, backup cells, and long-term monitoring. Each product also has its own risks; the relevant prescribing information and individual assessment must guide decisions.[2,5] A donor transplant may also be an option to discuss. Its suitability and risks depend on the donor’s and patient’s circumstances. Ask your usual hematology team and the transplant team to compare current care, transplantation, and gene therapy together.
How to read results from studies of new medicines
Etavopivat: look at both crises and hemoglobin results. HIBISCUS (NCT04624659) studies an oral pyruvate kinase activator. The sponsor’s announced main phase 3 results showed a 27% reduction in the annual crisis rate compared with placebo, with both groups receiving standard care. At week 24, 48.7% versus 7.2% had a hemoglobin increase of more than 1 g/dL. These are company-reported results and do not amount to regulatory approval. Assessment still needs to take account of the full paper, safety data, and your circumstances.[6]
Mitapivat: improvement in anemia measures does not mean improvement in the pain endpoint has also been established. The phase 3 randomized RISE UP trial (NCT05031780) enrolled 207 people. The published abstract reported that 41% of the treatment group and 3% of the placebo group achieved the study-defined hemoglobin response. Annualized pain crisis rates were 2.6 and 3.1, respectively; the difference was not statistically significant. Serious adverse events occurred in 20% and 29% of participants, respectively. These percentages cannot directly predict an individual’s risk.[7] On October 30, 2026, the sponsor said that the target review date for the US supplemental application for sickle cell disease had been extended to February 1, 2027. A target date does not guarantee approval. Approval of this medicine for other anemias does not automatically apply to sickle cell disease.[8]
Risto-cel: early data still require long-term follow-up. BEACON (NCT05456880) studies another approach using base editing of the patient’s own cells. The paper reported an average follow-up of 6.6 months among 31 people who received an infusion. Investigators reported no severe vaso-occlusive crises during the observation window beginning more than 60 days after the last red blood cell transfusion. This does not mean that everyone had completed the 12-month primary endpoint assessment. One patient died from idiopathic pneumonia syndrome, and 12 experienced serious adverse events. This analysis was not prespecified, and both follow-up time and participant numbers were limited. It cannot guarantee long-term freedom from pain or absence of risk. The study used busulfan for myeloablation.[9] Do not directly compare endpoints with different definitions across studies.
Check older information for market withdrawals as well. In 2024, the US FDA announced that the manufacturer had voluntarily withdrawn Oxbryta (voxelotor) because of safety concerns. In 2023, the EU revoked authorization for Adakveo (crizanlizumab) because a confirmatory study did not confirm clinical benefit. The situation in one region cannot be assumed to apply elsewhere. Patients currently taking these medicines should contact their prescribing team to discuss alternatives.[13,14]
How to check a trial and prepare for screening
- Use the registration number on a registry such as ClinicalTrials.gov to check the study’s full name, phase, recruitment status, latest update, age limits, genotype requirements, required number of previous crises, previous treatments, and exclusion criteria. Status updates may lag. “Active, not recruiting” does not mean applications are still accepted, nor does that status alone show that treatment is effective or has failed.[10]
- Ask the specific study center to confirm the project name and number, whether places are currently available, whether it accepts international patients, and the language and screening arrangements. Ask the center to provide details of the lead investigator, ethics review, and informed consent materials. A hospital’s listing on a registry page, or a global recruitment status, is not enough to prove that the center has places available.
- Prepare hemoglobin typing or genetic reports, records of crises and emergency visits or hospital stays, transfusion and antibody records, a medication list and treatment responses, organ test results, and any history of stroke or infection. Include a one-page timeline stating whether you hope to improve anemia, pain, transfusion burden, or another problem. If reports are missing, ask whether the center can arrange the tests and who will pay. Do not stop medicines on your own or hide medical history to meet eligibility requirements.
- Ask the study team to explain randomization, whether there is a placebo, background treatment, extra study tests, known and unknown risks, and alternative care if you do not participate. Before signing, seek professional interpretation and explain your understanding back to the team. Children should also be helped to understand in a way suited to their age, with decisions made by the appropriate people as required locally.[11,12]
If you do not pass screening, ask the team to explain why, whether other studies may be suitable, and how your existing hematology care will continue. If an emergency occurs while you are waiting, seek care first, then inform the study team.
What to confirm before paying or traveling
In China, for drug clinical trials covered by the Regulations for the Implementation of the Drug Administration Law, sponsors and trial institutions must not charge participants fees related to the clinical trial. For clinical research covered by the Regulations on the Administration of Clinical Research and Clinical Translation of New Biomedical Technologies, initiating institutions and research institutions must not charge participants fees related to the clinical research.[15,16] These two rules apply to different research pathways. Not all cell therapies or clinical translation applications can automatically be classified under either one. Ask the research institution and ethics committee to explain which rule applies to the project and how specific costs are classified, including failed screening, failed collection or manufacturing, tests, and management of complications.
Ask the study center for an itemized written cost statement, and check with the hospital’s finance department and your insurer: how will research-related injuries be managed, and are there subsidies for travel, accommodation, a caregiver, interpretation, visa extensions, return visits, and lost earnings? Living and travel expenses cannot all be assumed to be reimbursable or to fall within the prohibition on charging fees. For research abroad, check local rules and project documents. Confirm the currency, advance payments, refund conditions, and written insurance preauthorization. A free study medicine does not mean all other expenses are free.[12,15,16]
Ask the center to state in writing the expected length of stay and circumstances that could extend it, who will arrange local emergency care and handle abnormal results, and whom to contact at night. Confirm which tests a local doctor can perform after you leave the country, who should receive the results, how often you need follow-up visits, and who pays. Ask whether the study medicine will remain available after the study ends or you withdraw, who will prescribe and pay for it, and how you will return to routine care. All of these depend on the protocol and institutional arrangements and cannot be guaranteed in advance.
Research participation is voluntary. In China, in research covered by the Measures for the Ethical Review of Life Science and Medical Research Involving Humans, participants or their guardians may withdraw unconditionally at any stage without being treated unfairly as a result.[17] Safe discontinuation of treatment, follow-up tests, handling of data already collected, and continuing care should be discussed separately with the study team. They must not be made conditions for permission to withdraw. For research abroad, check local rules and the consent form.[12] Withdrawal cannot undo myeloablation or an infusion that has already taken place, so ask about the consequences of each stage before treatment starts.
Frequently asked questions
1. If I find a registration number, can I book an appointment?
No. First check the status and eligibility requirements on the registry page, then ask the specific study center to confirm whether places are available, whether it accepts international patients, and how screening works.[10]
2. If I meet the age requirement on the Casgevy label, am I definitely eligible?
Not necessarily. Doctors also need to assess your disease, organ function, risks of collection and myeloablation, alternative treatments, and the local label. Requirements also differ by region.[2–4]
3. Does treatment using my own cells still require chemotherapy?
Casgevy and Lyfgenia, discussed above, require myeloablative conditioning, which carries risks including infection, bleeding, and effects on fertility. The treatment center should explain the specific medicines, schedule, and protective measures.[2,5]
4. If a paper reports no severe crises, does that mean a cure?
No. You need to consider the study definitions, when observation began, the number of participants, and follow-up duration. BEACON is an interim analysis with a limited number of participants. Long-term safety and effectiveness still need follow-up.[9]
5. If the study includes a placebo, will I stop my existing medicines?
That depends on the protocol. Before signing, ask whether standard care will continue and which medicines must be kept stable or stopped. Do not change treatment on your own.[11,12]
6. Can I withdraw at any time? Will I still receive care afterward?
Participation is voluntary. In Chinese studies covered by the ethical review measures, participants or their guardians may withdraw unconditionally at any stage without being treated unfairly as a result.[17] Safety monitoring, costs, and referrals can be discussed separately with the team; they are not conditions for withdrawal. Cell therapy steps already completed cannot be undone. For research abroad, check local rules and the consent form.[12]
7. If a Chinese hospital performs transplants, can it provide these products?
You cannot infer that. Ask the hospital to provide written details of the specific product or study number, its regulatory and ethics status, actual supply or recruitment, and whether it will accept your application.
8. What if I suddenly develop a fever while preparing to apply?
If your temperature reaches 38.5°C or higher, go immediately to a local emergency department or hospital and tell them you have sickle cell disease. Do not wait for the study center to reply. If your doctor has set a personal threshold for seeking care sooner, follow your individual emergency plan.[1]
Sources
Checked on November 6, 2026. Verify again before making travel or treatment decisions.
-
FDA: Casgevy Product Information; FDA: 2026 Expansion of the Pediatric Indication.
-
UK MHRA: Casgevy Expanded to Children Aged 5 Years and Older.
-
Novo Nordisk: Main HIBISCUS Phase 3 Results, April 2026; NCT04624659.
-
RISE UP Phase 3 Study, Lancet, PubMed Abstract; NCT05031780.
-
FDA: Informed Consent Guidance. This guidance reflects the US regulatory framework. The requirements where the project takes place and the consent form govern actual participation.
-
FDA: Safety Communication on the Voluntary Withdrawal of Oxbryta.